64 related articles for article (PubMed ID: 38630260)
1. The role of thymic stromal lymphopoietin in cutaneous disorders.
Jafari AJ; Rivera M; Hebert AA
Arch Dermatol Res; 2024 Apr; 316(5):123. PubMed ID: 38630260
[TBL] [Abstract][Full Text] [Related]
2. Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases.
Wang SH; Zuo YG
Front Immunol; 2021; 12():698522. PubMed ID: 34249003
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D3-elicited CD14+ human skin dendritic cells promote thymic stromal lymphopoietin-independent type 2 T-helper responses.
Brulefert A; Hoste A; Muller Q; Fauny JD; Mueller CG; Flacher V
Allergy; 2021 Jul; 76(7):2044-2056. PubMed ID: 33368331
[TBL] [Abstract][Full Text] [Related]
4. The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis.
Jariwala SP; Abrams E; Benson A; Fodeman J; Zheng T
Clin Exp Allergy; 2011 Nov; 41(11):1515-20. PubMed ID: 21672057
[TBL] [Abstract][Full Text] [Related]
5. Thymic stromal lymphopoietin regulates eosinophil migration via phosphorylation of l-plastin in atopic dermatitis.
Noh JY; Shin JU; Park CO; Lee N; Jin S; Kim SH; Kim JH; Min A; Shin MH; Lee KH
Exp Dermatol; 2016 Nov; 25(11):880-886. PubMed ID: 27304220
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone but not tacrolimus suppresses TNF-α-induced thymic stromal lymphopoietin expression in lesional keratinocytes of atopic dermatitis model.
Mizuno K; Morizane S; Takiguchi T; Iwatsuki K
J Dermatol Sci; 2015 Oct; 80(1):45-53. PubMed ID: 26198442
[TBL] [Abstract][Full Text] [Related]
7. Role of thymic stromal lymphopoietin in allergy and beyond.
Ebina-Shibuya R; Leonard WJ
Nat Rev Immunol; 2023 Jan; 23(1):24-37. PubMed ID: 35650271
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
9. Tezepelumab: First Approval.
Hoy SM
Drugs; 2022 Mar; 82(4):461-468. PubMed ID: 35184265
[TBL] [Abstract][Full Text] [Related]
10. Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year.
Blauvelt A; de Bruin-Weller M; Simpson EL; Chen Z; Ardeleanu M; Rossi AB
Dermatol Ther (Heidelb); 2022 Jan; 12(1):9-13. PubMed ID: 34994968
[TBL] [Abstract][Full Text] [Related]
11. Itch: Pathogenesis and treatment.
Sutaria N; Adawi W; Goldberg R; Roh YS; Choi J; Kwatra SG
J Am Acad Dermatol; 2022 Jan; 86(1):17-34. PubMed ID: 34648873
[TBL] [Abstract][Full Text] [Related]
12. Diphenylcyclopropenone plays an effective therapeutic role by up-regulating the TSLP/OX40L/IL-13 pathway in severe alopecia areata.
Gong Y; Luo L; Li L; He X; Lu W; Sha X; Mao Y
Exp Dermatol; 2021 Feb; 30(2):278-283. PubMed ID: 33325128
[TBL] [Abstract][Full Text] [Related]
13. Physiology and Pathophysiology of Itch.
Cevikbas F; Lerner EA
Physiol Rev; 2020 Jul; 100(3):945-982. PubMed ID: 31869278
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
